within Pharmacolibrary.Drugs.ATC.C;

model C09XA54
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.13333333333333333,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>This drug is a fixed-dose combination tablet of aliskiren (a direct renin inhibitor), amlodipine (a calcium channel blocker), and hydrochlorothiazide (a thiazide diuretic), used for the treatment of hypertension (high blood pressure) in adults when blood pressure is not adequately controlled with single or dual therapy. Aliskiren/amlodipine/hydrochlorothiazide combination is an approved antihypertensive therapy.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic studies found for the fixed-dose triple combination; parameters are estimated based on known PK of individual components in healthy adults following oral administration.</p><h4>References</h4><ol><li>Walid M Ebeid, Ehab F Elkady, Asmaa A El-Zaher, Ramzia I El-Bagary, Gabor Patonay,Simultaneous Determination of Aliskiren Hemifumarate, Amlodipine Besylate and Hydrochlorothiazide in Spiked Human Plasma Using UPLC-MS/MS.,Journal of chromatographic science,2015<a href='https://pubmed.ncbi.nlm.nih.gov/25575509/'>https://pubmed.ncbi.nlm.nih.gov/25575509/</a></li><li>Alexander V Murray, Wolfgang Koenig, Juan Garcia-Puig, Samir Patel, Alkaz Uddin, Jack Zhang,Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study.,Journal of clinical hypertension (Greenwich, Conn.),2012<a href='https://pubmed.ncbi.nlm.nih.gov/23205748/'>https://pubmed.ncbi.nlm.nih.gov/23205748/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09XA54;
